In contrast, other risk markers for plaque instability, such as an unfavorable risk profile and systemic inflammation—as assessed by CRP and prototypical cytokines TNF-α and IL-6—were not associated with SMI-assessed IPN. This evidence concerns the gene TNF and bile duct papillary neoplasm.